For years, to talk about Alzheimer’s was to talk about a diagnosis that came too late and to which there were few answers. Today the scenario is different because advances in the knowledge of the disease, new treatments and tools such as biomarkers in blood or artificial intelligence are changing the way to investigate and address it. Pascual Sánchez-Juan, neurologist and scientific director of the CIEN Foundation, sees reasons for optimism, alt…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
For years, to talk about Alzheimer’s was to talk about a diagnosis that came too late and to which there were few answers. Today the scenario is different because advances in the knowledge of the disease, new treatments and tools such as biomarkers in blood or artificial intelligence are changing the way to investigate and address it. Pascual Sánchez-Juan, neurologist and scientific director of the CIEN Foundation, sees reasons for optimism, alt…